Neoplasm Proteins
"Neoplasm Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (TUMOR MARKERS, BIOLOGICAL) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Descriptor ID |
D009363
|
MeSH Number(s) |
D12.776.624
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Proteins".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Proteins".
This graph shows the total number of publications written about "Neoplasm Proteins" by people in this website by year, and whether "Neoplasm Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1980 | 1 | 0 | 1 | 1982 | 2 | 1 | 3 | 1983 | 0 | 1 | 1 | 1985 | 1 | 1 | 2 | 1986 | 1 | 0 | 1 | 1987 | 3 | 1 | 4 | 1988 | 2 | 0 | 2 | 1989 | 1 | 0 | 1 | 1991 | 1 | 0 | 1 | 1992 | 2 | 1 | 3 | 1993 | 1 | 2 | 3 | 1994 | 2 | 3 | 5 | 1995 | 4 | 4 | 8 | 1996 | 6 | 3 | 9 | 1997 | 3 | 3 | 6 | 1998 | 3 | 1 | 4 | 1999 | 5 | 5 | 10 | 2000 | 8 | 15 | 23 | 2001 | 9 | 3 | 12 | 2002 | 12 | 5 | 17 | 2003 | 17 | 4 | 21 | 2004 | 12 | 8 | 20 | 2005 | 8 | 5 | 13 | 2006 | 7 | 10 | 17 | 2007 | 9 | 8 | 17 | 2008 | 13 | 4 | 17 | 2009 | 7 | 9 | 16 | 2010 | 5 | 7 | 12 | 2011 | 8 | 6 | 14 | 2012 | 9 | 10 | 19 | 2013 | 10 | 9 | 19 | 2014 | 9 | 6 | 15 | 2015 | 8 | 8 | 16 | 2016 | 9 | 3 | 12 | 2017 | 5 | 3 | 8 | 2018 | 9 | 4 | 13 | 2019 | 9 | 8 | 17 | 2020 | 10 | 5 | 15 | 2021 | 9 | 2 | 11 | 2022 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Neoplasm Proteins" by people in Profiles.
-
Parriott G, Kee BL. E Protein Transcription Factors as Suppressors of T Lymphocyte Acute Lymphoblastic Leukemia. Front Immunol. 2022; 13:885144.
-
Lim SA, Zhou J, Martinko AJ, Wang YH, Filippova EV, Steri V, Wang D, Remesh SG, Liu J, Hann B, Kossiakoff AA, Evans MJ, Leung KK, Wells JA. Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers. J Clin Invest. 2022 02 15; 132(4).
-
Najem H, Marisetty A, Horbinski C, Long J, Huse JT, Glitza Oliva IC, Ferguson SD, Kumthekar PU, Wainwright DA, Chen P, Lesniak MS, Burks JK, Heimberger AB. CD11c+CD163+ Cells and Signal Transducer and Activator of Transcription 3 (STAT3) Expression Are Common in Melanoma Leptomeningeal Disease. Front Immunol. 2021; 12:745893.
-
Hwang J, Singh N, Braniecki M, Gok Yavuz B, Tsoukas MM, Quigley JG. Omacetaxine added to a standard acute myeloid leukaemia chemotherapy regimen reduces cellular FLIP levels, markedly increasing the incidence of eccrine hidradenitis. Br J Haematol. 2021 11; 195(3):e138-e141.
-
Imgruet MK, Lutze J, An N, Hu B, Khan S, Kurkewich J, Martinez TC, Wolfgeher D, Gurbuxani SK, Kron SJ, McNerney ME. Loss of a 7q gene, CUX1, disrupts epigenetically driven DNA repair and drives therapy-related myeloid neoplasms. Blood. 2021 09 02; 138(9):790-805.
-
Yesilkanal AE, Johnson GL, Ramos AF, Rosner MR. New strategies for targeting kinase networks in cancer. J Biol Chem. 2021 10; 297(4):101128.
-
Dai J, Zha Y, Foster CC, Luke JJ, Chmura SJ, Hoffman MD. Punctate Anetoderma After Colony-Stimulating Factor 1 Receptor and Programmed Cell Death 1 Blockade With Irradiation: Clinicopathologic Characterization of a Novel Eruption. JAMA Dermatol. 2021 08 01; 157(8):998-1000.
-
Dasgupta A, Chen KH, Lima PDA, Mewburn J, Wu D, Al-Qazazi R, Jones O, Tian L, Potus F, Bonnet S, Archer SL. PINK1-induced phosphorylation of mitofusin 2 at serine 442 causes its proteasomal degradation and promotes cell proliferation in lung cancer and pulmonary arterial hypertension. FASEB J. 2021 08; 35(8):e21771.
-
Capece D, D'Andrea D, Begalli F, Goracci L, Tornatore L, Alexander JL, Di Veroli A, Leow SC, Vaiyapuri TS, Ellis JK, Verzella D, Bennett J, Savino L, Ma Y, McKenzie JS, Doria ML, Mason SE, Chng KR, Keun HC, Frost G, Tergaonkar V, Broniowska K, Stunkel W, Takats Z, Kinross JM, Cruciani G, Franzoso G. Enhanced triacylglycerol catabolism by carboxylesterase 1 promotes aggressive colorectal carcinoma. J Clin Invest. 2021 06 01; 131(11).
-
Singhal SS, Mohanty A, Kulkarni P, Horne D, Awasthi S, Salgia R. RLIP depletion induces apoptosis associated with inhibition of JAK2/STAT3 signaling in melanoma cells. Carcinogenesis. 2021 05 28; 42(5):742-752.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|